Viridian Therapeutics (VRDN) executive compensation, 2026 proxy

Stephen Mahoney, Chief Executive Officer, was paid $6.8M in 2025, up 506% from $1.1M the year before. The CEO-to-median-employee pay ratio was 15:1, on median employee pay of $439,114.

Filed
April 17, 2026
Annual meeting
June 2, 2026
Pay year
2025
Named executives
5
CEO total pay
$6.8M+506% vs prior year
CEO to median employee
15:1median $439,114
CEO pay in equity
80%$5.4M in awards
Prior say-on-pay support
78%of votes cast
CEO Total Compensation
$6,776,249For fiscal year 2025
CEO Pay Ratio
15.4:1Compared to median employee
Say-on-Pay Support
78%At 2025 annual meeting
Bonus Payout Percentage
150%Of target annual bonus

How Mahoney was paid

$6.8M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary10%Stock awards16%Option awards65%Non-equity incentive9%All other compensation0%

Named executive officers

ExecutiveTotal
Stephen MahoneyChief Executive Officer$6,776,249
Seth HarmonChief Financial Officer$2,642,779
Jennifer TousignantChief Legal Officer$2,351,915
Thomas BeethamChief Operating Officer$3,761,182
Dr. Radhika TripuraneniChief Medical Officer$4,080,466

What changed and why

  • $6.8MCEO total compensation was $6,776,249 for fiscal 2025 compared to $1,117,454 in the prior year.
  • 4.4%Base salaries for named executive officers increased by 4.4% to 9.0% at the start of 2025.
  • 150%Annual cash bonuses were paid at 150% of target levels based on corporate milestone achievements.
  • 75%Long-term incentives were granted using a mix of 75% stock options and 25% restricted stock units.
  • 78%Approximately 78% of votes cast supported the say-on-pay advisory vote at the 2025 annual meeting.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.